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Abstract 26 
Background 27 
Eczema, synonymous with atopic eczema or atopic dermatitis, is a chronic skin 28 
disease that has a similar impact on health-related quality of life as other chronic 29 
diseases. The proposed research aims to provide a comprehensive systematic 30 
assessment of the economic evidence base available to inform economic modelling 31 
and decision making on interventions to prevent and treat eczema at any stage of the 32 
life course. Whilst the Global Resource of Eczema Trials (GREAT) database collects 33 
together the effectiveness evidence for eczema there is currently no such systematic 34 
resource on the economics of eczema. It is important to gain an overview of the current 35 
state of the art of economic methods in the field of eczema in order to strengthen the 36 
economic evidence base further. 37 
Methods/design 38 
The proposed study is a systematic review of the economic evidence surrounding 39 
interventions for the prevention and treatment of eczema.  Relevant search terms will 40 
be used to search MEDLINE, EMBASE, Database of Abstracts of Reviews of Effects, 41 
Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled 42 
Trials, NHS Economic Evaluation Database, Health Technology Assessment, 43 
Cumulative Index to Nursing and Allied Health Literature,  Econ Lit, Scopus, Cost-44 
Effectiveness Analysis Registry and Web of Science in order to identify relevant 45 
evidence. To be eligible for inclusion studies will be primary empirical studies 46 
evaluating the cost, utility or full economic evaluation of interventions for preventing or 47 
treating eczema. Two reviewers will independently assess studies for eligibility and 48 
perform data abstraction. Evidence tables will be produced presenting details of study 49 
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characteristics, costing methods, outcome methods and quality assessment. The 50 
methodological quality of studies will be assessed using accepted checklists.  51 
Discussion 52 
The systematic review is being undertaken to identify the type of economic evidence 53 
available, summarise the results of the available economic evidence and critically 54 
appraise the quality of economic evidence currently available to inform future 55 
economic modelling and resource allocation decisions about interventions to prevent 56 
or treat eczema. We aim to use the review to offer guidance about how to gather 57 
economic evidence in studies of eczema and/or what further research is necessary in 58 
order to inform this. 59 
Registration 60 
PROSPERO registration number: CRD42015024633 61 
Keywords:  62 
Eczema; Economics; Costs; Health-related quality of life; Cost effectiveness 63 
 64 
BACKGROUND 65 
 66 
In the UK the lifetime prevalence of eczema is estimated to be between 16% and 20% 67 
making it the commonest inflammatory skin condition in children and it has been 68 
increasing in “western style” environments (Williams et al. 2008, Williams 2005, Kay 69 
et al 1994). In the UK, the age-sex standardised incidence and lifetime prevalence of 70 
eczema has increased between 2001 and 2005 from  9.58 per 1000 to 13.58 per 1000 71 
patients and 77.78 per 1000 to 115.26 per 1000 respectively (Simpson et al, 2009). 72 
Up to 50% of childhood cases will experience recurrence in adulthood (Williams 2005). 73 
Eczema is largely managed in primary care.  Skin conditions are the commonest new 74 
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reason patients consult their GP (Schofield et al, 2011). Eczema has been found to 75 
have a similar impact on health-related quality of life as other common childhood 76 
conditions such as asthma and diabetes (Lewis-Jones, 2006). Eczema impacts quality 77 
of life by causing itching, sleep loss and social stigma for the child. Families may also 78 
suffer from sleep loss and time taken off work to accompany children to health 79 
appointments (Paller et al, 2002). The condition is associated with atopy so children 80 
with the condition are more likely to develop asthma and allergic rhinitis (Hon et al, 81 
2012). It is also believed that eczema has large cost implications. For instance, in 82 
1995-6 the total annual UK cost of eczema in children aged 5 years or younger was 83 
estimated as £47 million (£80 per child) (Emerson et al, 2001). Looking at a broader 84 
age range, the UK total annual cost was estimated to be around £465 million, of which 85 
£125 million were NHS costs, £297 million  costs incurred by patients and £42 million 86 
by society in terms of lost productivity (price year not reported) (Herd et al, 1996). 87 
These UK based estimates of the total annual UK costs of eczema are now dated, the 88 
estimates were based on small samples [146 in Herd et al 1996 and 1523 in Emerson 89 
et al 2001], and the range of treatments available has increased and is likely to 90 
increase in the future with the addition of new biologics (Howell et al, 2015).  91 
 92 
Despite Eczema being common there remain many unknowns about how to prevent 93 
and treat the condition. The James Lind Alliance (JLA) Priority Setting Partnership 94 
(PSP) on eczema illustrates this (http://www.jla.nihr.ac.uk/priority-setting-95 
partnerships/eczema and Batchelor et al, 2013). The JLA facilitates disease specific 96 
PSPs that bring together patients, carers and health professionals to identify and 97 
prioritise research for the treatment uncertainties of the disease of interest 98 
(http://www.jla.nihr.ac.uk/). The eczema PSP was established in 2010 with partners 99 
5 
 
drawn from academic, NHS and charitable sectors and resulted in 14 treatment 100 
uncertainties being prioritised (Batchelor et al., 2013).  101 
 102 
In order to draw together the effectiveness evidence of interventions for eczema, The 103 
Global Resource of Eczema Trials (GREAT) database was established (Nankervis et 104 
al, 2011) and includes details of over 600 systematic reviews and randomised 105 
controlled trials. It does not, however, identify or bring together the economic literature 106 
on eczema and thus this review attempts to do this. There is likely to be less economic 107 
evidence, compared to effectiveness data, for eczema. Indeed the English National 108 
Institute of Health and Care Excellence (NICE) has only considered economic models 109 
for two areas of eczema care: an educational intervention for those with eczema aged 110 
under 12 (NICE, 2007) and Tacrolimus and pimecrolimus for atopic eczema (NICE, 111 
2004). It is, therefore, important to identify the current state of economic evidence 112 
addressing eczema in order to inform the design of future economic research in the 113 
area.  114 
 115 
The proposed systematic review will address the following four research questions: 116 
 117 
1. What type of health economic evidence has been used in the evaluation of 118 
the prevention and treatment of atopic eczema? 119 
 120 
2. Are interventions to prevent and treat atopic eczema cost effective? 121 
 122 
3. What is the quality of the health economic evidence for the prevention and 123 
treatment of atopic eczema? 124 
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 125 
4. What are the current gaps in the existing research? 126 
 127 
METHODS/DESIGN 128 
Protocol and registration 129 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols 130 
(PRISMA-P) statement recommendations were used to develop the methods for this 131 
systematic review and will be used in reporting the results from the study (Shamseer 132 
et al 2015). This protocol has been registered in the International Prospective Register 133 
of Systematic Reviews (PROSPERO) CRD42015024633. Should protocol 134 
amendments be necessary, these will be documented including details of the date, 135 
changes made and the rationale for changes. 136 
 137 
Literature search 138 
The following electronic databases will be searched: MEDLINE, EMBASE, Cumulative 139 
Index to Nursing and Allied Health Literature, Cochrane Central Register of Controlled 140 
Trials, Database of Abstracts of Reviews of Effects, Cochrane Database of Systematic 141 
Reviews, NHS Economic Evaluation Database, Econ Lit, Scopus, Health Technology 142 
Assessment, Cost-Effectiveness Analysis Registry and Web of Science. Search 143 
results will be downloaded to EndNote version 7 where duplicates will be identified 144 
and removed. 145 
 146 
Reference lists of potential eligible studies, reviews, guidelines or other sources will 147 
be screened for additional literature. Authors of published abstracts and conference 148 
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proceedings will be contacted by email to establish if a full paper has since been 149 
published in the grey literature. 150 
 151 
The search strategy (with interface and coverage dates) is available in Appendix 1 to 152 
this protocol. 153 
 154 
Eligible studies 155 
A study will be included if it reports primary data on cost and/or outcome (utility or 156 
willingness to pay) data on atopic eczema. The primary interest is in full economic 157 
evaluations (Cost effectiveness, cost utility, cost benefit, cost minimisation) although 158 
other partial economic evidence will also be included where the study has an explicit 159 
economic objective, this is likely to include cost consequence analyses, cost analyses, 160 
utility assessment, or willingness to pay/accept studies. There will be no restriction on 161 
the study designs used in the economic studies so, for example, economic studies 162 
conducted alongside randomised controlled trials, as part of observational studies, or 163 
as decision model-based analyses will be included. Nor will there be any restrictions 164 
on type of setting. The search was undertaken on the 9th October 2015 so only studies 165 
published before this date are included. Only full text articles published in the English 166 
Language will be included, abstracts and letters will be excluded. Where two or more 167 
studies appear to be reporting on the same dataset or using the same model, the most 168 
comprehensive paper will be included unless each paper reports on a different aspect 169 
or in relation to a different jurisdiction/population (in the case of modelling studies).  170 
 171 
DATA COLLECTION 172 
Study selection 173 
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Two independent reviewers will assess the titles and abstracts retrieved in the 174 
literature search against our inclusion criteria. In a second stage, full-text articles for 175 
those seeming to fit the criteria or where there is uncertainty about relevance will be 176 
retrieved and their eligibility assessed according to criteria set out in Table 1. Where 177 
disagreements occur a third reviewer will be involved. 178 
 179 
Data abstraction and management 180 
Data will be extracted independently by two reviewers and entered into an electronic 181 
data extraction form developed in Microsoft Excel, with the third reviewer consulted in 182 
case of disagreements that cannot be resolved between the two reviewers. A full list 183 
of the extraction fields can be found in Table 2. The data extraction form was piloted, 184 
modified (where necessary) and reviewers’ responses calibrated on the basis of two 185 
pre-identified studies (one modelling study and one non-model based paper). The data 186 
extracted will be analysed in a narrative/descriptive manner focusing on the methods, 187 
results and quality of studies included with the aim of identifying gaps in the evidence, 188 
areas of strength and areas in need of methodological improvement.  189 
 190 
If the necessary data are available, the results will be discussed as subsets for different 191 
age groups (e.g. child/adult/elderly) and/or different skin disease severities and/or 192 
world regions and/or health care settings. 193 
 194 
Quality assessment and data presentation 195 
Two reviewers will independently evaluate the quality of included studies in order to 196 
assess the risk of bias. Studies will be assessed using a published checklist based on 197 
a modified version of the Consolidated Health Economic Evaluation Reporting 198 
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Standards (CHEERS) framework (Husereau et al, 2013) (see Table 3). In addition, 199 
model based economic evaluations will also be assessed using the Phillips criterion 200 
(Phillips et al, 2004, 2006) (see Table 4 for extraction table). Any discrepancies will be 201 
discussed and resolved by a third reviewer. These evaluations will be included in any 202 
publication as supplementary material. 203 
  204 
Methodological variation between studies is likely to prevent a pooling of economic 205 
data in the form of a meta-analysis and therefore, results of the studies will be 206 
presented and discussed in a qualitative manner according to study type. 207 
 208 
DISCUSSION 209 
This systematic review will provide a comprehensive assessment of the type and 210 
quality of economic research used in the evaluation of interventions to prevent and 211 
treat eczema. The results of the review are likely to be written up in multiple 212 
publications, one focusing on an overview of the state of the art with additional papers 213 
focusing in more detail on particular methodologically aspects (for instance, the 214 
methods used in modelling studies).  The review will report the range of cost 215 
effectiveness estimates found for interventions to prevent and treat atopic eczema, 216 
which may be useful in informing clinicians and decision makers about the relative 217 
value of different interventions for eczema and enable the value of eczema 218 
interventions to be compared with the cost effectiveness for other interventions in other 219 
disease areas. That is, it may help decision makers, on the basis of current information 220 
(if sufficient), to be able to answer questions about how to allocate limited resources 221 
between eczema and other disease areas and once allocated to eczema how to use 222 
those limited resources efficiently to maximise outcomes from eczema care. The 223 
10 
 
review will also be of interest to methodologists interested in the range and quality of 224 
economic studies in this clinical field.  Finally this systematic review will help identify 225 
gaps in the current evidence base surrounding the economics of eczema to inform 226 
further research efforts in this area.  227 
 228 
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